Patients are treated according to clinical subtypes of breast cancer, hormone receptor-positive (HR+), HER2-positive (HER2+), or triple-negative breast cancer (TNBC), based on the expression of hormone receptor (HR) and HER2 protein6. This evidence concerns the gene NR4A1 and breast carcinoma.